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1. Introduction 
Synucleinopathies are a group of neurodegenerative disorders that share common 
pathological intracellular deposits that contain aggregates of the protein ǂ-synuclein. 
Substantial evidence suggests that fibril formation by ǂ-synuclein is a critical step in the 
development of Parkinson's disease (PD). Indeed, in vitro, ǂ-synuclein forms fibrils with 
morphologies and staining characteristics similar to those extracted from disease-affected 
brains. Also, three single-point mutations and duplication or triplication of the ǂ-synuclein 
locus correlate with early onset of PD.  
However, the function of ǂ-synuclein remains unknown. A significant portion of ǂ-
synuclein is localized within membrane fractions, and especially synaptic vesicles associated 
with vesicular transport processes. These observations suggest that ǂ-synuclein has a role in 
vesicular trafficking. Although ǂ-synuclein belongs to a group of natively unfolded 
proteins, there is strong evidence that the membrane affinity of the protein induces an ǂ-
helical conformation. A large number of studies have investigated ǂ-synuclein–lipid 
interactions in the search for a physiological function, as well as to understand this potential 
membrane involvement in the pathogenesis of ǂ-synuclein. In this review, we will 
predominantly focus on current opinion about the native wild-type ǂ-synuclein–lipid 
interactions and the structure of ǂ-synuclein that is established at the membrane surface. 
However, it should be noted that membranes have been reported to both accelerate and 
inhibit the fibril formation of ǂ-synuclein, although this will not be the focus of the present 
review. 
2. Intrinsically disordered proteins 
A significant number of proteins involved in protein deposition diseases have been seen to 
be intrinsically disordered proteins. Well-known examples include amyloid ǃ-protein and 
tau protein in Alzheimer's disease, prion protein (PrP) in prion diseases, exon 1 region of 
huntingtin in Huntington's disease, and ǂ-synuclein in PD (Fink, 2005). 
It has been estimated that more than 30% of eukaryotic proteins have disordered regions 
that are greater than 50 consecutive residues (Dunker et al., 2001). This term “disordered 
protein” refers to proteins that in their purified state at neutral pH, have been either shown 
experimentally or predicted to lack an ordered structure; such proteins are also known as 
natively unfolded, or intrinsically unstructured. Disordered proteins, or disordered regions 
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of a protein, lack specific tertiary structure and can be composed of an ensemble of 
conformations (Fink, 2005). Intrinsically unstructured proteins are frequently involved in 
important regulatory functions in the cell, and the lack of intrinsic structure is in many cases 
removed when the protein binds to its target molecule. Some functional advantages of these 
proteins might be an ability to bind to several different targets, the precise control of their 
binding thermodynamics, and their involvement in cell-cycle control and both 
transcriptional and translational regulation (Wright & Dyson, 1999). Gunasekaran et al. 
proposed that disordered proteins provide a simple solution to the need for large 
intermolecular interfaces while maintaining smaller proteins, and hence a smaller genome 
and a smaller cell size. For monomeric proteins with extensive intermolecular interfaces, 
such proteins would need to be 2-3-fold larger, and this would either increase intracellular 
crowding or enlarge the size of the cell by some 15% to 30%, owing to the increase in the 
sequence length (Gunasekaran et al., 2003). 
3. Synucleinopathies 
Protein-conformation-dependent toxicity is an emerging theme in neurodegenerative 
disorders, including the synucleinopathies (Ulrih et al., 2008). The group of 
synucleinopathies comprises many neurodegenerative diseases, among which the best 
known and most common is PD, but it also includes Lewy body dementia, multiple system 
atrophy, neurodegeneration with brain iron accumulation type I, diffuse Lewy body disease, 
and Lewy body variant of Alzheimer's disease (Arawaka et al., 1998; Gai et al., 1998; 
Spillantini et al., 1997; Wakabayashi et al., 1997). These are all brain amyloidoses with the 
common characteristic of pathological intracellular inclusions of aggregates that have ǂ-
synuclein as the key component (Spillantini et al., 1997; Wakabayashi et al., 1997).  
PD is characterized by the death of neurons that produce dopamine and are located in the 
substantia nigra pars compacta brain region (see below). This is accompanied by the 
appearance of Lewy bodies and Lewy neurites (Galvin et al., 1999). Lewy bodies are 
spherical protein inclusions that are found in the cytoplasm of surviving substantia nigra 
neurons, and they consist of a dense core surrounded by a halo of radiating fibrils of ǂ-
synuclein; they also contain a variety of other proteins. The fibrils seen in PD are structurally 
similar to those in the amyloid diseases, and they appear as linear rods of 5 nm to 10 nm 
diameter (Fink, 2006). PD affects more than 1% of the population over 65 years of age 
(Goedert, 2001), and typical symptoms include tremor, slow movements, fine motor 
difficulties, and loss of postural reflexes (Jankovic, 2008). The cause of PD remains 
unknown, but considerable evidence suggests a multifactorial etiology that involves genetic 
susceptibility and environmental factors (Fink, 2006). However, substantial evidence 
indicates that aggregation of ǂ-synuclein is a critical step in the etiology of PD (Trojanowski 
& Lee, 2003). 
Most cases of PD are of the late onset idiopathic type (Beyer, 2007). Evidence for an 
important role for ǂ-synuclein in triggering PD also emerged when certain mutations were 
discovered that are associated with rare inherited autosomal dominant cases of PD. While, 
as indicated, familial early onset PD is caused by overexpression of ǂ-synuclein due to 
duplication (Chartier-Harlin et al., 2004) or triplication (Singleton et al., 2003) of the ǂ-
synuclein gene locus, three specific point mutations have also been identified: A53T in a 
large kindred of Italian and Greek origin (Polymeropoulos et al., 1997); A30P in a German 
family (Kruger et al., 1998); and E46K in a Spanish family (Zarranz et al., 2004). 
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4. Alpha-synuclein 
In brain homogenates, ǂ-synuclein represents 0.5% to 1% of the total protein (Iwai et al., 
1995). Northern blotting and in-situ hybridization in human and mice have show relatively 
high expression of ǂ-synuclein in a restricted number of brain regions, one of which is the 
substantia nigra (Abeliovich et al., 2000; Lavedan, 1998). Here, ǂ-synuclein is localized in the 
presynaptic terminals (George et al., 1995; Iwai et al., 1995), with about 15% found in the 
membrane fraction (Lee et al., 2002); after synaptosomal lysis, ǂ-synuclein is in the soluble 
fraction (Iwai et al., 1995). 
Although the normal physiological function of ǂ-synuclein remains unknown, it appears to 
be involved in maintenance of the synaptic vesicle reserve pool of the brain (Davidson et al., 
1998; Fortin et al., 2004; Iwai et al., 1995; Nuscher et al., 2004). However, other roles for ǂ-
synuclein have been considered: roles in lipid metabolism and transport (Scherzer et al., 
2003; Sharon et al., 2001; Willingham et al., 2003), vesicle docking at the membrane (Larsen 
et al., 2006), exocytosis (Srivastava et al., 2007),  lipid organisation (Madine et al., 2006) and 
prevention of oxidation of unsaturated lipids  (Zhu et al., 2006). To date, no conclusive 
evidence showing the precise role of ǂ-synuclein in cell physiology has been provided. 
4.1 Primary sequence 
Alpha-synuclein is a small (140 amino acid; 14 kDa) highly acidic protein (Figure 1), and it is 
intrinsically disordered under physiological conditions in vitro (Bisaglia et al., 2009; Fink, 
2006). The first 89 residues are composed almost entirely of seven 11-amino-acid imperfect 
repeats, with a consensus sequence of KTKEGV (George et al., 1995). This strongly resembles 
sequence motifs found in exchangeable apolipoproteins, which are believed to constitute 
amphipathic helical lipid-binding domains (Segrest et al., 1992). This 11-residue periodicity is 
broken in one point by the insertion of four uncharged amino acids, separating units 4 and 5. 
There are no Cys or Trp residues in the ǂ-synuclein sequence (George et al., 1995). 
The structure of ǂ-synuclein can be divided into three regions (Figure 1). The N-terminal 
domain (residues 1-60) is positively charged and contains five of the imperfect repeats (Fink, 
2006; George et al., 1995). The sequence 61-95 is the most hydrophobic portion of the 
protein, and this was originally described as the “non-amyloid-beta component” (NAC) of 
Alzheimer´s disease plaques (Takeda et al., 1998). Several studies have defined this region as 
responsible for ǂ-synuclein aggregation and ǃ-sheet formation (Bodles et al., 2001; Giasson 
et al., 2001). The homologous ǃ-synuclein, which is distinct from ǂ-synuclein by the absence 
of the central hydrophobic sequence, is much less prone to self-aggregation. The interaction 
between ǃ-synuclein and ǂ-synuclein has been argued to inhibit aggregation (Park & 
Lansbury, 2003). The highly acidic C-terminal domain of ǂ-synuclein is rich in Pro and 
acidic residues, with a predominance of Glu residues over Asp (George et al., 1995). This 
domain contains three of the four Tyr residues, at positions 125, 133 and 136; the fourth Tyr 
residue is at position 39. It has been shown that monomeric ǂ-synuclein has a more compact 
structure than expected for a completely unfolded polypeptide, and this compactness has 
been linked to its inhibition of fibril formation due to burial of the hydrophobic NAC 
domain (Bertoncini et al., 2005; Dedmon et al., 2005). In addition, it has been shown that the 
1–102 and 1–110 C-terminal-truncated ǂ-synuclein fragments, but not that of 1–120, are 
efficient in the promotion of ǂ-synuclein aggregation. The negatively charged 104, 105, 114 
and 115 residues in the C-terminus have been suggested to be responsible for reduced ǂ-
synuclein aggregation and a lack of seeding of wild-type ǂ-synuclein (Murray et al., 2003). 
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Fig. 1. Top: Amino-acid sequence of human ǂ-synuclein. The imperfect 11-mer repeats are as 
indicated, with the predominant KTKEGV consensus sequences underlined. The locations of 
the three point mutations that have been linked to early-onset PD (A30T, E46K, A53T) are 
shown in bold type, and the four Tyr residues are shaded. Bottom: The ǂ-synuclein 
sequence can be divided into three regions: the N-terminus adopts an ǂ-helix upon binding 
to lipids, the hydrophobic NAC domain can form ǃ-sheet structure, and the negatively 
charged C-terminus is unstructured. 
4.2 Alpha-synuclein structure under physiological conditions 
Weinreb et al. were the first to attempt to define the secondary structure of ǂ-synuclein. 
Sedimentation of ǂ-synuclein under physiological conditions is slower than for globular 
proteins of a similar molecular weight, suggesting an elongated structure of the native 
protein. Circular dichroism has demonstrated the lack of ǂ-synuclein secondary structure in 
solution: 68% as random coils and less than 2% as helical content. The reminder of the 
protein is ǃ-sheet, although it is difficult to quantify the ǃ-sheet structure by circular 
dichroism. Fourier-transform infrared spectroscopy has confirmed that native ǂ-synuclein is 
unstructured. The conformational properties of ǂ-synuclein were not changed by heat 
denaturation and were independent of ǂ-synuclein concentration, salt concentration, 
chemical denaturants and pH. These features prompted the conclusion that under 
physiological conditions, ǂ-synuclein exists as a mixture of rapidly equilibrating extended 
conformers,  and that it is representative of a class of natively unfolded proteins (Weinreb et 
al., 1996). With a slightly different isolation protocol, circular dichroism showed 9% ǂ-helix, 
35% ǃ-sheet, and 56% random coil structure in solution (Narayanan & Scarlata, 2001). 
Dedmon et al. (2005) used paramagnetic relaxation enhancement and nuclear magnetic 
resonance (NMR) to show interactions between different parts of the ǂ-synuclein molecule. 
Some ǂ-synuclein mutants were prepared, with the insertion of nitroxide-labeled cysteine 
residues, which allowed the observation of short-life-time interactions. Partial condensation 
of ǂ-synuclein is driven by long-range contacts between residues 30-100 in the center of the 
molecule, and residues 120-140 in the C-terminal tail. It appears that this interaction can 
shield the NAC region (residues 61-95) from aggregation, which is the most hydrophobic 
part of ǂ-synuclein (Dedmon et al., 2005). Bertoncini et al. used a similar methodology to 
show that the most important interaction is a hydrophobic cluster that comprises the C-
terminal part of the NAC region (residues 85-95) and the C-terminus (residues 110-130), 
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which is probably mediated by Met116, Val118, Tyr125 and Met127. Within the C-terminal 
domain, residues 120-130 contact residues 105-115, and the region around residue 120 also 
interacts with the N-terminus around residue 20. These long-range interactions that stabilize 
the monomeric conformations of ǂ-synuclein also inhibit its oligomerization and 
aggregation. The autoinhibitory conformations fluctuate in the range of nanoseconds to 
microseconds (Bertoncini et al., 2005). Consistent with this, small-angle X-ray scattering 
analysis has shown that the radius of gyration, which is used to describe the dimensions of 
polypeptide chain, is ~40 Å with native ǂ-synuclein, which is much larger than that 
predicted for a folded globular protein of 140 residues (15 Å), although it is significantly 
smaller than that of a fully unfolded random coil (52 Å) (Uversky et al., 2001). 
Using an atomic-force-microscopy-based single-molecule mechanical unfolding 
methodology, Sandal et al. (2008) studied the ǂ-synuclein conformation equilibrium under 
various conditions. Their method allowed the measuring of the force required for unfolding 
a single protein molecule. It was thus possible to detect conformers with a lifetime that was 
longer than 10-3 s, which due to their longevity, might be the most biologically relevant 
structures. In 10 mM TRIS/HCl buffer solution at pH 7.5, the ǂ-synuclein secondary 
structure contains a random coil (38.2%) and ǃ-structure (7.3%) (Sandal et al., 2008). 
5. Fibril formation 
In-vitro studies of recombinant ǂ-synuclein have demonstrated that purified ǂ-synuclein 
forms fibril aggregates that resemble those found in Lewy bodies (Serpell et al., 2000). In 
contrast to its helical secondary structure in the presence of lipids, ǂ-synuclein monomers 
form soluble oligomers (sometimes referred to as protofibrils) that can undergo a 
conformational change from disordered to predominantly beta secondary structure. These 
oligomers can assemble and form insoluble fibrils, which are found in inclusion bodies, 
together with other proteins (Conway et al., 2000; Fink, 2006; Wood et al., 1999). 
Extensive data suggest that the first step of fibrillogenesis is the formation of a partially 
folded intermediate that promotes self-association of ǂ-synuclein and formation of various 
oligomeric species (Uversky et al., 2001). Factors that increase the concentrations of these 
intermediates will favor aggregation (Fink, 2006). Protein aggregation and the kinetics of 
fibril formation typically appear sigmoidal, and they are usually attributed to a nucleated 
polymerization process in which the initial lag phase corresponds to the requirement for the 
formation of critical nuclei; the subsequent exponential growth phase corresponds to fibril 
elongation, and the final plateau is ascribed to the exhaustion of the soluble monomers and 
intermediates (Ulrih et al., 2008). 
All three of the above-mentioned PD-related point mutations have been shown to accelerate 
ǂ-synuclein aggregation in vitro (Uversky, 2007). The A53T and A30P point mutations both 
accelerate oligomer formation, although only A53T readily forms large amyloid fibrils 
(Conway et al., 2000). E46K appears to be even more effective in the promotion of aggregate 
formation in cultured cells than these other two mutations (Pandey et al., 2006). 
As fibril formation of native ǂ-synuclein occurs in most cases of synucleinopathies, most 
studies have deal with the mechanisms that trigger this process. Both physical and chemical 
factors have been demonstrated to affect this aggregation process (Lundvig et al., 2008).  
As mentioned above, it is believed that interactions between the C-terminus and the central 
portion of ǂ-synuclein can prevent or minimize its aggregation/fibril formation. As the 
majority of hydrophobic interactions in the C-terminal of ǂ-synuclein arise through its three 
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Tyr, we created Tyr to Ala mutants to examine the importance of these Tyr residues in fibril 
formation of ǂ-synuclein in vitro. This was completely inhibited in the timescale over which 
measurements were made (70 hours) when the three C-terminal Tyr were replaced with Ala. 
In addition, substitution of Tyr133 by Ala also inhibitted fibril formation, whereas the 
individual Y125A and Y136A mutants showed limited inhibition. Replacement of Tyr39 by 
Ala also resulted in substantial inhibition of fibril formation. Structural analysis showed that 
the Y133A ǂ-synuclein mutant has a substantially different conformation, as it is rich in ǂ-
helical secondary structure, as compared with wild-type ǂ-synuclein and its other mutants. 
However, no formation of any tertiary structure was seen, as judged from the near-UV 
circular-dichroism spectra. These observations suggest that the long-range intramolecular 
interactions between the N-terminal and C-terminal of ǂ-synuclein are crucial for the 
process of fibril formation (Ulrih et al., 2008).  
6. Alpha-synuclein and membranes 
6.1 Lipid-binding domains 
A characteristic feature of the ǂ-synuclein amino-acid sequence is the set of seven 
degenerate 11-residue repeating motifs. These are reminescent of the amphipathic ǂ-
helical domains of the exchangeable apolipoproteins, which mediate a variety of lipid and 
protein interactions (Davidson et al., 1998, George et al., 1995). Amphipathicity 
corresponds to the segregation of polar and nonpolar residues to the two opposite faces of 
the ǂ-helix, a distribution that is well suited for membrane binding (Drin & Antonny, 
2009). 
Depending upon the distribution of residues to the polar and nonpolar faces of the helices, 
Segrest et al. divided the apolipoprotein ǂ-helices into different classes: class A helices bind 
lipids and are characterized by a clustering of basic residues at the polar/nonpolar interface 
and acidic residues at the center of the polar face, while class G helices are implicated in 
protein interactions and are characterized by a random radial distribution of charged 
residues to the polar face of the helix (Segrest et al., 1992). Davidson et al. subjected the 
entire ǂ-synuclein sequence to helical wheel analysis and identified five potential 
amphipathic ǂ-helices that encompass all of the 11-mer repeats and some of the adjacent 
amino acids. The first four of these five theoretical helices share the defining properties of 
class A2 lipid-binding helices, and they are distinguished by clustered basic residues at the 
polar-apolar interface and positioned ±100° from the center of the nonpolar face, with a 
preponderence of Lys over Arg, and the presence of Glu residues on the polar face. The ǂ-
helix on the fifth 11-mer repeat resembles a class G helix, and it is thus a candidate for 
protein-protein interactions (Davidson et al., 1998).  
There is a notable feature that can be used to distinguish between putative amphipathic ǂ-
synuclein helices and those in the exchangeable apolipoproteins: the Thr residues at the 
center of the nonpolar faces of helices 2-4 (Davidson et al., 1998). Although polar, these can 
reside on the nonpolar face of the helix due to its relatively long aliphatic side chain (Segrest 
et al., 1992). Thr are conserved among the ǂ-synuclein sequences from canary, human and 
rat, suggesting that they indeed have an important function. Another unique aspect of the ǂ-
synuclein 11-mer repeat sequences is the absence of Pro, which in exchangeable 
apolipoproteins introduces helix-breaking hairpin turns. In contrast, ǂ-synuclein helices 1-4 
appear to be punctuated by nonpolar residues that are predicted to disrupt the 
amphipathicity of a helix (Davidson et al., 1998). 
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6.2 Lipid and membrane selectivity 
Data that have documented the tendency of ǂ-synuclein to colocalize with synaptic vesicles 
in vivo (Maroteaux et al., 1988) and the presence of the 11-residue repeated domains in a 
pattern similar to that found in the apolipoproteins (George et al., 1995) sparked a series of 
studies to determine the ǂ-synuclein lipid-binding ability. Alpha-synuclein interactions with 
membranes have been found to be one of the most contentious areas regarding this protein 
(Fink, 2006), as there have been numerous reports on sometimes completely contradicting 
results, and as there might be major differences between the situation in vivo and in vitro. 
Also, membranes have been reported to both accelerate (Lee et al., 2002) and inhibit 
(Narayanan & Scarlata, 2001; Zhu & Fink, 2003) ǂ-synuclein fibril formation, so this 
probably reflects the varying conditions used in the different studies (Zhu & Fink, 2003). 
All three of these ǂ-synuclein mutations occur within the N-terminus, which is responsible 
for its membrane binding, hence suggesting an effect on membrane interactions (Fortin et 
al., 2010). The A30P ǂ-synuclein mutation, and to a lesser extent that of A53T, disrupts the 
helical structure of ǂ-synuclein (Bussell & Eliezer, 2001), although it does not significantly 
affect the structure of membrane-associated ǂ-synuclein (Bussell & Eliezer, 2004). The E46K 
ǂ-synuclein mutant binds to negatively charged vesicles with a higher protein/lipid ratio 
than does wild-type ǂ-synuclein (Choi et al., 2004), while A30P affects the localization, and 
presumably the membrane binding, of ǂ-synuclein in vivo (Fortin et al., 2010). 
6.2.1 Membrane interactions in vitro 
It is generally accepted that ǂ-synuclein preferentially interacts with small unilamellar 
vesicles (SUVs) containing negatively charged head groups (Davidson et al., 1998; Jo et al., 
2000) or interfacial packing defects (Kamp & Beyer, 2006; Nuscher et al., 2004), and that 
upon SUV binding, ǂ-synuclein undergoes a conformational transition from an intrinsically 
disordered state to an ǂ-helical structure (Davidson et al., 1998; Jo et al., 2000; Nuscher et al., 
2004). Various combinations of charged and uncharged lipids have been used in these 
studies. These negatively charged acidic phospholipids include phosphatidylglycerol (PG), 
phosphatidic acid (PA), phosphatidylserine (PS) and phosphatidylinositol (PI), while the 
uncharged, neutral lipids commonly used include phosphatidylcholine (PC) and 
phosphatidylethanolamine (PE) (Valenzuela, 2007).  
The interactions of ǂ-synuclein with membranes have been shown to affect the properties of 
both the protein and the membranes, and both electrostatic and hydrophobic interactions 
are important in the protein-bilayer association (Zhu et al., 2003). There are several factors 
that are believed to have central roles in modulation of the binding equilibrium of ǂ-
synuclein to membranes, including chemical properties of the membranes (Davidson et al., 
1998; Jo et al., 2000), ionic strength of the solution (Davidson et al., 1998; Zhu et al., 2003), 
vesicle size, or more precisely, the curvature of the phospholipid surface (Davidson et al., 
1998; Narayanan & Scarlata, 2001; Rhoades et al., 2006), and mass ratio of ǂ-synuclein to the 
lipids (Zhu & Fink, 2003). Here, an overview of some of the more important findings 
regarding the lipid specificities of ǂ-synuclein are given. 
Davidson et al. were the first to demonstrate that ǂ-synuclein binds only to acidic 
phospholipids and preferentially to vesicles with smaller diameters. Circular dichroism 
spectroscopy was used to determine the effects of this lipid binding on the secondary 
structure of ǂ-synuclein. In buffer solution, ǂ-synuclein is mainly unstructured, with less 
than 3% of the structure as ǂ-helix. Incubation of ǂ-synuclein with vesicles made of a 
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mixture of acidic and neutral phospholipids is accompanied by a large increase in its ǂ-
helical content. Alpha-synuclein does not bind to SUVs or multilamellar vesicles composed 
of PC only, or of a mixture of PC and PE. Here, ǂ-synuclein binds to SUVs containing at 
least 30% to 50% acidic lipids, per vesicle weight. Comparisons of the ability of ǂ-synuclein 
to bind to vesicles of different sizes, as SUVs with 20 nm to 25 nm diameters and large 
unilamellar vesicles (LUV) with 125 ±30 nm diameter, have shown that ǂ-synuclein does not 
bind to vesicles that contained neutral 1-palmitoyl 2-oleoyl PC (POPC) alone. Also, binding 
to LUVs composed of POPC/1-palmitoyl 2-oleoyl PA (POPA) was less than to SUVs of the 
same composition (Davidson et al., 1998). 
Binding to negatively charged SUVs was confirmed in another study where they incubated 
ǂ-synuclein together with vesicles and then fractionated the solution with gel filtration 
chromatography. Alpha-synuclein eluted together with the SUV fraction when incubated 
with either POPC/POPA or POPC/1-palmitoyl 2-oleoyl PS (POPS) phospholipids, while its 
binding to vesicles composed of POPC alone was not detected (Perrin et al., 2000). 
Althought in nervous tissue PA comprises approximately 1% to 3% of the total 
phospholipids, while PS is more abundant (12% to 22% of the total phospholipids) (Sastry et 
al., 1985), it is difficult to relate these values directly to the local composition of specific 
membranes inside the cell, since these lipids are not distributed evenly in the cell and are 
generated and metabolized rapidly (Perrin et al., 2000). 
Using thin-layer chromatography overlay, it has been shown that ǂ-synuclein binds to the 
brain or commercially available lipids PE, PI and lyso-PE. These interactions were much 
weaker with POPS and brain PS, and absent with POPC, POPA, sphingomyelin and 
cholesterol (Jo et al., 2000). Surprisingly, in contrast with a previous report (Davidson et al., 
1998), ǂ-synuclein does not bind to PA, which was attributed to the properties of the thin-
layer chromatography overlay method. Replacing PC with PE in acidic lipid vesicles greatly 
increased the binding of ǂ-synuclein (Jo et al., 2000). Althought both PE and PC are neutral 
phospholipids that have similar electrostatic properties, they differ in their head-group 
orientation, lipid bilayer packing, and hydrogen-bonding capacity (Hauser et al., 1981, as 
cited in Jo et al., 2000). When the neutral head-groups are tightly packed, PE forms a lipid 
monolayer with high negative curvature (Bazzi et al., 1992). It is believed that ǂ-synuclein 
can relieve this negative curvature strain, and hence stabilize the PE/acidic lipid vesicles. 
This study also showed that both SUVs and multilamellar vesicles composed of 
POPC/POPS induce ǂ-helical secondary structures, which suggests that the vesicle size 
does not impact on the ǂ-synuclein secondary structure. With the neutral charged PE in the 
presence of acidic phospholipids (PA and PI), this significant increases the ǂ-synuclein ǂ-
helicity. However, it should be emphasized that the changes in ǂ-synuclein secondary 
structure are much lower in the presence of neutral PC in combination with negatively 
charged lipids (Jo et al., 2000). 
In contrast to previous studies that used prolonged incubation times and mechanical 
separation of the products, and which found that ǂ-synuclein only bound to SUVs 
composed of acidic phospholipids (Davidson et al., 1998; Jo et al., 2000; Perrin et al., 2000), in 
another study, the association between ǂ-synuclein and lipids was viewed immediately 
after the addition of lipids to ǂ-synuclein. Data were then obtained either by monitoring the 
change in intrinsic fluorescence emanating from four ǂ-synuclein Tyr residues, or by adding 
the Laurdan fluorescent probe to the vesicles. Surprisingly, ǂ-synuclein bound with similar 
affinities to LUVs composed of the negatively charged POPS and the electrically neutral 
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POPC. This initial binding did not induce changes in the secondary structure of ǂ-synuclein. 
This study also supported the role of the ǂ-synuclein C-terminus in membrane binding, by 
showing that lowering the pH of folded ǂ-synuclein, which reduces the negative charge of 
ǂ-synuclein, greatly increases the binding affinity without altering the secondary structure 
(Narayanan & Scarlata, 2001). 
Fluorescence correlation spectroscopy was used as a tool for rapid and quantitative analysis 
of the lipid binding of ǂ-synuclein. Some studies have confirmed the importance of the 
negatively charged lipids (PA and PS) for ǂ-synuclein binding to LUVs with 120 nm 
diameter, when no pre-incubation of ǂ-synuclein and the vesicles was used. Alpha-
synuclein has a significantly higher affinity for vesicles that contain some POPA, over those 
that contain an equivalent amount of POPS. The reason for this could be the polar POPA 
head-group, which is smaller in size compared to that of POPS and might therefore be able 
to pack more closely together in a lipid bilayer, producing a higher charge density. Alpha-
synuclein shows slightly higher binding affinity to POPE compared to POPC (Rhoades et al., 
2006). Combined with other data in the literature (Davidson et al., 1998; Jo et al., 2000; 
Nuscher et al., 2004), these suggest that each molecule of ǂ-synuclein can bind to a lipid 
bilayer patch composed of ≤85 acidic lipid molecules, corresponding in the case of POPS to a 
weight ratio of bound protein to total lipid of approximately 1:5. Interestingly, at higher ǂ-
synuclein concentrations, the amount of bound ǂ-synuclein decreases, suggesting a 
destabilization of the membrane. This study also confirmed the importance of electrostatic 
interactions for the binding between ǂ-synuclein and the lipids (Rhoades et al., 2006). 
The binding of ǂ-synuclein to SUVs has been monitored by measuring the changes in 
intrinsic fluorescence emanating from the four Tyr residues in ǂ-synuclein. These data have 
suggested that ǂ-synuclein binds to both negatively charged and electrically neutral SUVs, 
although slightly weaker for the latter. This binding to electrically neutral vesicles is 
presumably due to electrostatic interactions between the negatively charged C-terminal 
region of ǂ-synuclein and the positively charged choline. Binding to different types of 
vesicles was also detected in high ionic strength solutions. These data indicate that for ǂ-
synuclein binding to lipids, not only are electrostatic interactions important, but also 
hydrophobic interactions. The influence of ǂ-synuclein binding to the membrane has also 
been examined. Due to the differences in the excitation spectra and polarisation of the 
Laurdan dye after incubation of dipalmitoyl PA (DPPA)/dipalmitoyl PC (DPPC) and 
dipalmitoyl PG (DPPG)/DPPC SUVs with ǂ-synuclein, this study concluded that ǂ-
synuclein is inserted deep into the membrane and does not remain bound only on the 
surface. A lack of significant penetration of ǂ-synuclein into the DPPC vesicle bilayer was 
observed. Random coil–helix structure transition was most notable when SUVs composed of 
DPPG or dipalmitoyl PS (DPPS) or their mixtures with DPPC or dipalmitoyl PE (DPPE) 
were used. The amount of helix induced was smaller for DPPA/DPPC. SUVs made of DPPC 
only do not trigger the formation of the ǂ-synuclein ǂ-helix structure; presumably ǂ-
synuclein binds to the surface of these vesicles due to electrostatic interactions, but does not 
induce the helical structure (Zhu et al., 2003). 
The small diameter of the SUVs leads to curvature stress in the bilayer, which results in a 
rather broad phase transition that is centered at ~4-5 °C below the chain-melting phase-
transition temperature (Tm), and thus vesicles made of DPPC undergo melting transition at 
36 °C rather than at 41 °C (Gaber & Sheridan, 1982). Using isothermal titration calorimetry, 
differential scanning calorimetry (Nuscher et al., 2004), spin label electron paramagnetic 
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resonance (EPR), and fluorescence spectroscopy (Kamp & Beyer, 2006), it has been shown 
that ǂ-synuclein affects the lipid packing in neutral SUVs. Here ǂ-synuclein induces chain 
ordering below the Tm, but not in the liquid crystalline state of zwitterionic vesicle 
membranes. Binding of ǂ-synuclein leads to an increase in the temperature and 
cooperitivity of the phase transition, which was attributed to defect healing in the curved 
vesicle membranes. Binding to the vesicles also induces coil-helix transitions of ǂ-synuclein 
(Kamp & Beyer, 2006; Nuscher et al., 2004). SUVs made of POPC/POPG at a molar ratio of 
1:1 and 2:1 cause ǂ-helix formation in the structure of ǂ-synuclein, and this is more 
pronounced at the 1:1 ratio. A helix structure is not observed in LUVs of the same 
composition. This again hightlights the importance of the negative charge and size of lipid 
vesicles for ǂ-synuclein ǂ-helix formation. A more important finding is the formation of the 
helical structure by binding to SUVs of neutrally charged DPPC under the Tm and not above 
that temperature (Nuscher et al., 2004). 
Recently, Bartels et al. used circular dichroism spectroscopy and isotermal titration 
calorimetry to investigate peptide fragments from different domains of the full-length ǂ-
synuclein protein. They showed that membrane recognition of the N-terminus is essential 
for the cooperative formation of helical domains in the protein. This suggests that the 
membrane-induced helical folding of the first 25 residues of ǂ-synuclein might be driven 
simultaneously by electrostatic attraction and by changes in lipid ordering (Bartels et al., 
2010). 
6.2.2 Membrane interactions in vivo  
Compared with the ǂ-synuclein–lipid interaction in vitro, the interaction of ǂ-synuclein with 
membranes in cells is less well understood. Cole et al.  investigated ǂ-synuclein interactions 
with intracellular lipid stores in cultured cells treated with high concentrations of fatty 
acids. Here, ǂ-synuclein accumulated on phospholipid monolayers surrounding 
triglyceride-rich lipid droplets and protected the stored triglycerides from hydrolysis. 
Chemical cross-linking experiments led to the suggestion that dimers or trimers of ǂ-
synuclein were associated with the droplet surface (Cole et al., 2002). 
Alpha-synuclein can be imported into cells (Sung et al., 2001) and can be secreted from cells, 
althought it lacks a conventional signal sequence for secretion (Lee et al., 2005). Lee et al. 
reported that a portion of ǂ-synuclein is stored in the lumen of vesicles in the cytoplasm, 
and that the ǂ-synuclein in vesicles might be secreted through an unconventional exocytosis 
pathway. This study also demonstrated that intravesicular ǂ-synuclein is more prone to 
aggregation than cytosolic ǂ-synuclein, and that aggregated forms of ǂ-synuclein are also 
secreted from cells (Lee et al., 2005). They thus used a series of deletion mutants and 
recombinant peptides to determine the amino-acid sequence motifs of ǂ-synuclein that were 
required for its membrane translocation. The N-terminal region and the NAC peptide were 
shown to be necessary for translocation, althought the NAC was less effective than the N-
terminal region. This thus suggested that the 11-amino acid repeat sequences bind to the 
lipid bilayer and that this binding interaction is crucial for ǂ-synuclein translocation. 
Cellular uptake of ǂ-synuclein was not significantlly affected by treatment with inhibitors of 
endocytosis, suggesting that this occurs via a mechanism distinct from normal endocytosis 
(Ahn et al., 2006). 
Sharon et al. showed that free fatty acids have specific roles in the formation and 
maintenance of the soluble ǂ-synuclein oligomers, and they suggested that ǂ-synuclein 
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might be a fatty-acid-binding protein (Sharon et al., 2001). In contrast, a later NMR study 
excluded high-affinity binding of fatty-acid molecules to specific ǂ-synuclein sites (Lucke et 
al., 2006). Exposure of living mesencephalic neurons to polyunsaturated fatty acids  (PUFAs) 
increased the ǂ-synuclein oligomer levels, whereas saturated fatty acids decreased these. 
Here, ǂ-synuclein interacts with the free PUFAs to form the first soluble oligomers, which 
then aggregate into insoluble high-molecular-weight complexes (Sharon et al., 2003a). 
Indeed, elevated PUFA levels have been detected in the soluble fractions of PD and Lewy 
bodies dementia brains. The levels of saturated and monounsaturated fatty acids did not 
change in these PD brains or in cells overexpressing ǂ-synuclein, which indicated that ǂ-
synuclein is involved specifically in the maintenance of PUFA levels (Sharon et al., 2003b). 
Using binding assays, it has been demonstrated that ǂ-synuclein binds saturably and with 
high affinity to detergent-resistant membranes, to lipid rafts, in permeabilized HeLa cells, 
and in the presence of synaptosomal membranes from transgenic mice expressing human ǂ-
synuclein. The A53T ǂ-synuclein mutation has no detectable effects on this binding, while 
the A30P mutation disrupts the association, which supports the specificity of the interaction 
(Fortin et al., 2004). It should also be mentioned that both of these mutations do not 
generally affect the interactions of ǂ-synuclein with artificial membranes (Perrin et al., 2000), 
probably because these membranes fail to reproduce the full characteristics of lipid rafts 
(Fortin et al., 2004). In contrast, the A30P mutation distrupts ǂ-synuclein association with 
native membranes, such as those of axonal transport vesicles, lipid droplets produced in 
HeLa cells by the administration of oleic acid, and yeast (Cole et al., 2002; Jensen et al., 1998; 
Outeiro et al., 2003). Alterations in the electrophoretic mobility of ǂ-synuclein upon 
membrane binding have confirmed its binding to lipid rafts, with this interaction resistant to 
digestion of the rafts with proteinase K, which suggests that the lipids, rather than proteins, 
are required. This assumption is also supported by high affinity binding of ǂ-synuclein to 
artificial membranes that do indeed mimic lipid rafts. Cholesterol does not appear to be 
required for the binding, but rather for maintenance of raft integrity; sphingolipid also 
appears not to be crucial for these interactions (Kubo et al., 2005). 
Similar to previous reports (Davidson et al., 1998; Perrin et al., 2000), Kubo et al. reported 
that ǂ-synuclein binding requires acidic phospholipids, with a preference for PS. Synthetic 
PS with defined acyl chains did not support this binding when used individually, with the 
combination of 18:1 PS and PS with polyunsaturated acyl chains required both to bind to 
and to shift the electrophoretic mobility of ǂ-synuclein. The addition of 18:1 PC to 20:4 PS, or 
conversely, the addition of 20:4 PC to 18:1 PS, also promoted ǂ-synuclein binding. The 
requirement for both monounsaturated and polyunsaturated acyl chains suggests that the 
interaction of ǂ-synuclein requires membranes with two distinct phases: lipid rafts in a 
liquid-ordered phase, and the rest of the cell membrane in a liquid-disordered phase. Alpha-
synuclein binds with higher affinity to artificial membranes with the PS head-group on the 
polyunsaturated fatty acyl chain rather than on the oleoyl side chain, apparently reflecting 
an interaction of ǂ-synuclein with both the acyl chain and the head-group (Kubo et al., 
2005). 
In contrast to artificial membranes, the interactions of ǂ-synuclein with biological 
membranes are highly dynamic and they show rapid dissociation. Thus, rather than 
electrostatic interactions, Kim et al. suggested the involment of hydrophobic interactions. 
Furthermore, the interactions of ǂ-synuclein with cellular membranes occured only in the 
presence of nonprotein and nonlipid cytosolic components, which distinguished it from the 
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spontanous interaction with artificial membranes. Here, addition of a cytosolic preparation 
to the artificial membranes resulted in similar binding of ǂ-synuclein as for biological 
membranes (Kim et al., 2006). 
Lipid rafts contain a lot of the ganglioside GM1, and it has been suggested that the 
gangliosides mediate or facilitate the association of ǂ-synuclein with neuronal membranes 
(Martinez et al., 2007). However, recently Di Pasquale et al. identifed a ganglioside-binding 
domain in ǂ-synuclein that showed a marked preference for interactions with GM3, which is 
a minor brain ganglioside for which the expression increases with age; the Lys34 and Tyr39 
residues were shown to have critical roles in the GM3 recognition by ǂ-synuclein (Di 
Pasquale et al., 2010). 
7. Structural properties of membrane-bound α-synuclein 
High resolution structural and dynamics information of ǂ-synuclein in its lipid-bound state 
appear to be sufficient for the development of a better understanding of the physiological 
role of ǂ-synuclein, as well as to identify the structural features that appear to be relevant to 
ǂ-synuclein misfolding (Ulmer et al., 2005). However, despite the abundance of structural 
information for soluble proteins, relatively little is known about the structures of membrane-
associated proteins in the physiologically important lipid bilayer environment (Jao et al., 
2008). Consistent with this, the conformation of membrane-bound ǂ-synuclein still remains 
unclear and somewhat contradictory.  
Several biophysical methods have provided valuable insights into the structural features of 
the disordered and folded ǂ-synuclein, including circular dichroism spectroscopy 
(Davidson et al., 1998; Chandra et al., 2003; Perrin et al., 2000), fluorescence spectroscopy 
(Rhoades et al., 2006), NMR (Bisaglia et al., 2005; Bussel & Eliezer, 2001, 2003; Bussel et al., 
2005; Chandra et al., 2003; Dedmon et al., 2005; Eliezer et al., 2001; Ulmer et al., 2005), and 
EPR (Bortolus et al., 2008; Drescher et al., 2008; Georgieva et al., 2008; Jao et al., 2004, 2008). 
Binding of ǂ-synuclein to anionic membranes induces folding of its N-terminal part into an 
amphipathic helix, whereas the C-terminus (residues ~98-140) remains unstructured 
(Bisaglia et al., 2005; Bussel & Eliezer, 2003; Chandra et al., 2003; Davidson et al., 1998; 
Eliezer et al., 2001; Ulmer et al., 2005). The helical content of ǂ-synuclein is much lower in 
buffer and in the presence of zwitterionic membranes (Davidson et al., 1998; Zhu & Fink; 
2003). 
It has generally been proposed that the natural binding target of ǂ-synuclein in vivo is the 
synaptic vesicles, the surface topology of which is most closely approximated in vitro by 
synthetic lipid vesicles (Bisaglia et al., 2005; Bussel & Eliezer, 2003; Bussell et al., 2005; 
Chandra et al., 2003; Jao et al., 2004; Ulmer et al., 2005). The slow tumbling rate of intact 
phospholipid vesicles has hindered direct studies of the vesicle-bound conformation of ǂ-
synuclein using solution NMR methods (Georgieva et al., 2008). Consequently, most of the 
structural information available concerns studies where detergent micelles were used as 
membrane-mimetic environments, because their small size facilitates high-resolution 
structural analysis by NMR. The conformation of micelle-bound ǂ-synuclein has thus been 
thoroughly investigated, and there is a general consensus on the presence of two curved 
helices, with a break in the ǂ-synuclein 38−44 region (Bisaglia et al., 2005; Bussell & Eliezer, 
2003; Chandra et al., 2003; Ulmer et al., 2005). On the contrary, the structure of ǂ-synuclein 
bound to lipid vesicles, which would be more relevant physiologically, remains a matter of 
debate. EPR analyses of ǂ-synuclein derivatives bound to SUVs have provided evidence for 
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an elongated helical structure that is devoid of any significant tertiary packing (Jao et al., 
2004), or they have suggested a broken helical structure (Bortolus et al., 2008; Drescher et al., 
2008). A number of recent studies have highlighted the ongoing debate regarding the 
physiologically relevant form, as the bent or extended membrane-bound helix (Figure 2). 
 
 
Fig. 2. Illustrations of the generally proposed ǂ-synuclein structures on (a) micelles (bent helix 
model) and (b) SUVs (elongated helix model) (Jao et al., 2008; Trexler & Rhoades, 2009).  
7.1 Helix periodicity 
Several studies have raised the question of the periodicity of the helix that is formed upon 
binding of ǂ-synuclein to membranes. As indicated above, the N-terminus of ǂ-synuclein 
contains seven imperfect 11-residue repeats. Using site-directed spin-labeling, it has been 
shown that repeats 5–7 of ǂ-synuclein are bound to SUVs with an 11/3 periodicity (11 residues 
to complete three full turns) (Jao et al., 2004). Sodium dodecyl sulphate (SDS) micelle-bound 
ǂ-synuclein shows the same periodicity, as opposed to the 18/5 periodicity of an ideal ǂ-helix 
(Bussell et al., 2005). In this ideal 18/5 periodicity, there are 3.6 residues per turn and the 
rotation per residue is 100°. In the ǂ-synuclein 11/3 periodicity, the number of residues per 
turn is 3.67 and the rotation per residue is 98.18°. Using theoretical methods, it has indeed been 
concluded that the periodicity of ǂ-synuclein is 11/3, and that through the positioning of the 
charged residues, this has implications for ǂ-synuclein membrane binding. These calculations 
show that the energy penalty for a change in periodicity from the 18/5 to 11/3 on anionic 
membranes is overcome by the favorable solvation energy (Mihajlovic & Lazaridis, 2008). 
7.2 Analysis of α-synuclein structure by nuclear magnetic resonance 
Eliezer et al. were the first to use NMR spectroscopy to characterize the conformational 
properties of ǂ-synuclein when bound to lipid vesicles and lipid-mimetic detergent micelles. 
They demonstrated that only the first 100 residues of the N-terminal region of ǂ-synuclein 
bind to both SDS micelles and PA/PC vesicles and fold into an amphipathic helix, while the 
acidic C-terminal region of ǂ-synuclein remains unstructured (Eliezer et al., 2001). 
Ulmer et al. have described the structure and dynamics of ǂ-synuclein in the micelle-bound 
form according to solution NMR spectroscopy. In binding to SDS micelles or SDS micelles 
with dodecylPC (DPC), ǂ-synuclein forms two curved ǂ-helices (Figure 3), helix-N (Val3-Val37) 
and helix-C (Lys45-Thr92). These helices are connected by a well-ordered, extended linker in an 
unexpected anti-parallel arrangement, which is followed by another short extended region 
(Gly93-Lys97) that overlaps with a chaperone-mediated autophagy recognition motif and a 
predominantly unstructured highly mobile tail (Asp98-Ala140) (Ulmer et al., 2005). 
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Fig. 3. Structure of ǂ-synuclein bound to SDS micelles. Picture represents the two curved ǂ-
helices (Val3-Val37 and Lys45-Thr92), connected by extended linker. The disordered C-
terminus has been partially omitted. The image was generated from the PDB (accession 
number 1XQ8). 
Although the presence of the helix break in the micelle-bound state of ǂ-synuclein has been 
suggested to be a consequence of the small size of the micelle (Jao et al., 2004), the well-
ordered conformation of the helix-helix connector indicates a defined interaction of ǂ-
synuclein with the lipid surfaces, suggesting that when it is bound to larger diameter 
synaptic vesicles, this can act as a switch between this broken helix structure and the 
uninterrupted helix structure (Ulmer et al., 2005). Therefore, the presence or absence of the 
helical break in ǂ-synuclein appears to be the more controversial structural feature of ǂ-
synuclein when bound to lipids (Bisaglia et al., 2009). Other studies have also shown that 
there are two helical regions in the N-terminal sequence of ǂ-synuclein that are interrupted 
by a single helix break around residue 42 (Bisaglia et al., 2005; Bussel & Eliezer, 2003; 
Chandra et. al., 2003). Data from Bisaglia et al. show that the region of residues 61-95 (the 
NAC region) is partially embedded in the micelle (Bisaglia et al., 2005) 
Analysis of the dynamic processes of the ǂ-synuclein backbone on a fast timescale 
(picoseconds to nanoseconds) revealed the presence of three distinct helical regions that 
have greater mobility with respect to the other helical fragments: Ala30-Val37, Asn65-Val70, 
and Glu83-Ala89 (Ulmer et al., 2005). All three of these regions have two Gly residues in close 
sequential proximity, which might serve to mitigate a possible effect of ǂ-synuclein binding 
on membrane fluidity. The helix curvature is significantly less than predicted based on the 
native globular micelle shape, which indicates a deformation of the micelle by ǂ-synuclein. 
Ulmer et al. suggested that the interactions of the positively charged Lys side chains, which 
emanate sidewards from the helices, with the negatively charged headgroups of SDS can 
lead to the deformation of the globular micelle along the helix axes, to form a prolate, 
ellipsoid particle (Ulmer et al., 2005). 
As indicated above, there are four Tyr residues in ǂ-synuclein. One of these, Tyr39, is located 
in the break region. Bisaglia et al. (2005) suggested that this Tyr39 is buried in the SDS 
micelle and proposed that this insertion might protect ǂ-synuclein from aggregation (Zhou 
& Freed, 2004; Ulrih et al., 2008), as well as to protect Tyr39 from phosphorylation by p72syk 
tyrosine kinase (Negro et al., 2002, as cited in Bisaglia et al., 2005). This is in contrast with 
other models that have predicted that this Tyr39 is located either on the hydrophilic side of 
the helix or at the membrane-water interface (Bussell & Eliezer, 2003; Chandra et al., 2003; 
Jao et al., 2004; Mihajlovic & Lazaridis, 2008). 
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7.3 Analysis of α-synuclein structure by electron paramagnetic resonance  
EPR analysis of 47 singly labeled ǂ-synuclein mutants has shown that the membrane 
interactions are mediated by major conformational changes within seven of the N-terminal 
11-amino-acid repeats: these reorganize from highly dynamic structures into an elongated 
helical structure. The equivalent positions within each of these different repeats are located 
in structurally comparable positions with respect to the membrane proximity, which 
suggests a curved membrane-dependent ǂ-helical structure of ǂ-synuclein, wherein each of 
these 11-aminoacid repeats takes up three helical turns (Jao et al., 2004). The ǂ-synuclein 
helix is over 90 amino acids in length and it extends parallel to the curved membrane in a 
manner that allows the conserved Lys and Glu residues to interact with the zwitterionic 
headgroups, while the uncharged residues penetrate into the acyl-chain region (Jao et al., 
2008). This structural arrangement is significantly different from that of ǂ-synuclein in the 
presence of the commonly used membrane-mimetic detergent, SDS (Bisaglia et al., 2005, 
Ulmer et al., 2005). Thus these structural analyses also show that it is important to consider 
the lipid composition of any given bilayer, as this can have pronounced effects on the 
protein and bilayer structures (Jao et al., 2008). 
Several other independent studies have appeared, with contradictory results. In one such 
study (Bortolus et al., 2008), the 35-43 region of ǂ-synuclein bound to SUVs and to SDS 
micelles was investigated using site-directed spin labeling and EPR spectroscopy. The 
distance distributions were compatible with the presence of conformational disorder in this 
region, rather than for the formation of a continuous helical structure. These data showed 
that ǂ-synuclein shows very similar behavior in micelles and in SUVs, and they ruled out an 
unbroken helical structure of the region around residue 40. This propensity for helix 
breaking was confirmed by their molecular dynamics simulations of the 31-52 fragment 
interacting with a lipid bilayer (Bortolus et al., 2008). 
In a study by Drescher et al. (2008), four ǂ-synuclein mutants were prepared by inserting 
Cys residues labeled with the spin-label reagent (S-(2,2,5,5-tetramethyl-2,5-dihydro-1H-
pyrrol-3-yl)methyl methanesulfonothioate) (MTSL), with each containing one label in the 
proposed helix 1, and a second label in helix 2. Between the labeled Cys residues within the 
molecule the distance resulting from their binding to the membrane was measured using 
dual-frequency pulsing EPR (double electron-electron resonance). Consistent with a 
previous report (Bortolus et al., 2008), these data showed that ǂ-synuclein even adopts a 
two-helix, antiparallel arrangement on vesicles that are large enough to accommodate an 
extended helix, which suggests that this bent structure is also the preferred conformation of 
ǂ-synuclein on larger vesicles (Drescher et al., 2008). 
Also using pulsed dipolar EPR, Georgieva et al. came to somewhat different conclusions. 
Here the distances measured between the pairs of nitroxide spin labels introduced were 
close to those expected for a single continuous helix. To circumvent problems associated 
with SUVs and rodlike SDS micelles, here they used lipid bicelles (providing a lipid-bilayer 
structure, yet having a particle size nearly as small as that of micelles), which produced very 
similar results to liposomes while offering a major improvement in experimentally 
accessible distance ranges and resolution. According to these data, they suggested that 
when ǂ-synuclein is bound to SUVs, it forms a single ǂ-helix, without the intermediate 
region of the interruption. The idea that ǂ-synuclein can interconvert between these broken 
and extended helical forms was also suggested, and it thus remains possible that in vivo ǂ-
synuclein occupies one or the other form depending on conditions (Georgieva et al., 2008). 
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7.4 Analysis of α-synuclein structure with other methods 
Contradictory to these current models of membrane-bound ǂ-synuclein that have been 
deduced mostly from NMR studies, limited proteolysis experiments have indicated that the 
C-terminal part of membrane-bound ǂ-synuclein has a more rigid structure. The negatively 
charged C-terminus appears to bind Ca2+ in the presence of SDS micelles, and in doing so it 
becomes sufficiently rigid and structured to resist extensive proteolysis (de Laureto et al., 
2006). In another study based on site-directed fluorescence labeling, they also  examined the 
effects of Ca2+ on the acidic tail conformation of lipid-bound ǂ-synuclein (Tamamizu-Kato et 
al., 2006). Here, they suggested that the Ca2+ either bridges ǂ-synuclein to the membrane, 
possibly by coordinating with the negative charge on the ǂ-synuclein acidic tail and the 
acidic head-groups in the phospholipid bilayer, or it facilitates the traversing of the 
membrane bilayer by this segment of ǂ-synuclein (Tamamizu-Kato et al., 2006). 
Another study highlighted the role of the physical parameters of the membrane mimetic in 
determining the ǂ-synuclein conformation (Trexler & Rhoades, 2009). Single molecule 
Förster resonance energy transfer was used to probe the helical structure of ǂ-synuclein 
bound to SDS micelles and LUVs. Single and double Cys ǂ-synuclein mutants were 
engineered to allow for site-specific labeling with maleimide fluorophores. When bound to 
highly curved detergent micelles, ǂ-synuclein formed a bent-helix, whereas the structure of 
the elongated helix was adopted when bound to the more physiological 100-nm-diameter 
lipid vesicles (Trexler & Rhoades, 2009).  
Single-molecule Förster resonance energy transfer was also used to provide evidence for the 
structural interplay between the broken and extended ǂ-helix structures of ǂ-synuclein, as 
induced by the binding of ǂ-synuclein to SDS and phospholipid SUVs (Ferreon et al., 2009). 
The switch between a broken and an extended helical structure can be triggered by 
changing the concentrations of the binding partners or by varying the curvature of the 
binding surfaces presented by the micelles or bilayers composed of SDS. The use of lipid 
vesicles of various compositions showed that a low fraction of the negatively charged lipids, 
as similar to that found in biological membranes, was sufficient to drive ǂ-synuclein binding 
and folding that resulted in the induction of the extended helical structure (Ferreon et al., 
2009). 
The structure of the N-terminal domain of ǂ-synuclein has also been determined using 
theoretical methods (Mihajlovic & Lazaridis, 2008). This computional study of the binding of 
truncated ǂ-synuclein (residues 1-95) to planar bilayers showed that ǂ-synuclein forms a 
bent helix, with the largest bend around residue 47. This bending of the helix was not due to 
the protein sequence or membrane-protein interactions, but to the collective motions of the 
long helix (Mihajlovic & Lazaridis, 2008). 
8. Conclusions 
In this chapter, we have presented the state-of-the-art for the field of α-synuclein structure, 
and for its fibril formation and interactions with membranes. There are still many 
unanswered questions regarding the correlation between α-synuclein membrane affinity, 
and its function and its role in synucleinopathies. As the disruption of membranes by α-
synuclein correlates with the binding affinity of α-synuclein for particular membrane 
compositions and with the induced helical conformation of α-synuclein, this suggests that 
inappropriate membrane permeabilization is the cause of cell dysfunction, and even cell 
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death, in amyloid diseases. Protofibrillar or fibrillar α-synuclein results in a much more 
rapid destruction of membranes than soluble monomeric α-synuclein, which indicates that 
protofibrils or fibrils are likely to be significantly neurotoxic. Further studies of α-synuclein 
interactions with membranes are still very important to provide us with a fuller 
undertanding of the molecular mechanisms of its implications in Parkinson's disease.   
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